BioSpace News Archive

The Mental Health Commission of Canada and the Canadian Centre on Substance Use and Addiction applaud the federal government for putting mental health and addiction squarely on the map in its December 5th throne speech.

Kodiak Sciences Inc. (Nasdaq: KOD), today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes 900,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a price to the public of $46.00 per share.

Almac Group, the global contract development and manufacturing organisation, is delighted to announce it has won the “Innovation in Sponsorship” award during this year’s Irish Sponsorship Awards ceremony in Dublin.

The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, is hosting a multi-stakeholder meeting in Brussels on 12 December, focused on European market access to Advanced Therapy Medicinial Products (ATMPs).

Navidea Biopharmaceuticals, Inc. announced that they have executed agreements with five investors, including an existing investor, John K. Scott, Jr., to purchase approximately 2.1 million shares of the Company’s common stock, par value $0.001 per share, in a private placement for aggregate gross proceeds to Navidea of approximately $1.9 million.

Stemline Therapeutics, Inc. announced the appointment of Robert M. Francomano as Chief Commercial Officer.

CStone Pharmaceuticals announced the appointment of Ms. Shirley Zhao to the position of General Manager for Greater China and Head of Commercial.

Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, highlighted three upcoming ELZONRIS (tagraxofusp), presentations, including an oral presentation of ELZONRIS clinical data in myelofibrosis, at this year’s American Society of Hematology (ASH) Annual Meeting and Exposition, that is being held from December 7-10 in Orlando, FL.

3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for AuriNovo™, an investigational combination product for reconstruction of the outer ear in patients with microtia.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated preliminary data from its ongoing Phase 1 dose escalation study of CA-4948,